Vertex doses first patient with next type 1 diabetes cell therapy program, while padding its coffers with strong Q2
Vertex has dosed the first type 1 diabetes patient with its next cell therapy program, the Boston biotech said Tuesday as part of its quarterly earnings update.
Vertex’s first cell therapy program, VX-880, has impressed with early clinical results, showing a one-time infusion of these insulin-producing cells brought significant effects in the first handful of treated patients. Those results, presented at June’s American Diabetes Association annual conference, included two treated patients with over a year of follow-up who have remained free from using insulin with no severe hypoglycemic events.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
